The association of age and adverse events of PEG-asparaginase in a pediatric tertiary care hospital; a retrospective review

Abbott Lesleigh; Claveau Maia; Tang KenCameron JameasonGoulet Genevieve

首页> 外文期刊>European Journal of Haematology >The association of age and adverse events of PEG-asparaginase in a pediatric tertiary care hospital; a retrospective review

【24h】

The association of age and adverse events of PEG-asparaginase in a pediatric tertiary care hospital; a retrospective review

机译：The association of age and adverse events of PEG-asparaginase in a pediatric tertiary care hospital; a retrospective review

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相关主题

摘要

Background Pediatric patients have a better survival rate for lymphoid malignancies than adolescents and young adult patients (AYA) and current evidence suggests that asparaginase plays a role in improved response to treatment. This study aimed to evaluate if increasing age as a continuous variable demonstrated increasing toxicities to PEG-asparaginase (PEG-ASP) for those patients treated at a tertiary care pediatric hospital. Methods A retrospective chart review from 2007 to 2017 was conducted in the pediatric population at the Children's Hospital of Eastern Ontario (CHEO). Patients having received PEG-ASP were included. Event incidence and risk related to age at diagnosis were assessed through parameter estimates and Wald chi-square analysis. Results In total, 75 adverse events were observed: 34/186 (18.3) experienced allergic reactions, 8/186 (4.3) pancreatitis, 31/186 (16.7) thrombosis, and 2/186 (1.1) hemorrhage. One hundred and eighty two patients had complete information for inclusion in our model. A correlation between age at diagnosis and higher risk of allergic reaction (p < .001) and pancreatitis (p < .035) was observed. Conclusion Allergic reaction and pancreatitis following administration of PEG-ASP have a higher risk of occurrence as age of diagnosis increases up to 18 years of age. This includes the lower limit of traditionally defined AYA population of 15-39 and warrants precaution as PEG-ASP is included in older populations treatment regimens at pediatric centers.

著录项

来源
《European Journal of Haematology》 |2023年第1期|32-39|共8页
作者
Abbott Lesleigh; Claveau Maia; Tang KenCameron JameasonGoulet Genevieve;
展开▼
作者单位

University of Ottawa,Childrens Hosp Eastern Ontario;

Dept Pharm,Childrens Hosp Eastern Ontario;

Res Inst,Childrens Hosp Eastern Ontario;

展开▼
收录信息
原文格式 PDF
正文语种英语
中图分类血液及淋巴系疾病;
关键词
adolescent and young adults; adverse events; age; PEG-asparaginase; pegaspargase; side effects; ACUTE LYMPHOBLASTIC-LEUKEMIA; CANCER-ASSOCIATED THROMBOSIS; YOUNG-ADULTS; ADOLESCENTS; CHILDREN; HYPERSENSITIVITY; RECOMMENDATIONS; PEGASPARGASE; MANAGEMENT;

The association of age and adverse events of PEG-asparaginase in a pediatric tertiary care hospital; a retrospective review

摘要

著录项

相关主题

期刊订阅